Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
February 28, 2020 07:00 ET | Novartis International AG
Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr. Joerg...
NOVARTIS logo.jpg
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
February 11, 2020 01:15 ET | Novartis International AG
FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer...
Sandoz
Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
January 31, 2020 01:30 ET | Novartis International AG
Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements...
Novartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculaires
January 29, 2020 01:00 ET | Novartis International AG
Hausse du chiffre d’affaires net des activités poursuivies1 de 9% sur l’exercice entier (tcc2, +6% USD): Pharmaceuticals: cette unité opérationnelle progresse de 12% (tcc), sous l’impulsion de...
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
January 29, 2020 01:00 ET | Novartis International AG
Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and...
Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
January 29, 2020 01:00 ET | Novartis International AG
Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von Cosentyx (USD 3,6 Milliarden,...
NOVARTIS logo.jpg
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
December 09, 2019 14:45 ET | Novartis International AG
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3  Fewer known CAR-T cell therapy adverse...